PIEX GROUP Revenue and Competitors
Estimated Revenue & Valuation
- PIEX GROUP's estimated annual revenue is currently $9.6M per year.
- PIEX GROUP's estimated revenue per employee is $201,000
Employee Data
- PIEX GROUP has 48 Employees.
PIEX GROUP's People
Name | Title | Email/Phone |
---|
PIEX GROUP Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is PIEX GROUP?
Created in 1980, and now a recognized specialist of exporting healthcare products to Africa and Asia, Piex was recently acquired by a group of investors led by LBO France (together with BNPP Développement, AfricInvest, BPI and Trocadéro Capital), as the first pilar of an ambitious strategy aiming at enhancing and expanding access to genuine medicines and parapharmaceuticals across Africa, the Middle East and Asia. Key figures: 35 countries reached 90M€ revenues in 2017 800 references in stock 40 supplying manufacturers 350 customers
keywords:N/AN/A
Total Funding
48
Number of Employees
$9.6M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
PIEX GROUP News
In contrast, histone deacetylases (HDACs) remove acetyl groups from the ... VC: pIEx-4 empty vector control; Met: pIEx-4 vector containing...
To achieve PIEx status, an individual must successfully pass four certification programs: Continuous Improvement Manager, Lean Six Sigma...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 57 | 24% | N/A |
#2 | $19.7M | 127 | -17% | N/A |
#3 | N/A | 137 | 51% | N/A |
#4 | $22.3M | 203 | 10% | N/A |
#5 | $47.2M | 296 | 5% | N/A |